Read by QxMD icon Read

Arthritis & Rheumatology

Atul Deodhar, Lianne S Gensler, Joachim Sieper, Michael Clark, Cesar Calderon, Yuhua Wang, Yiying Zhou, Jocelyn H Leu, Kim Campbell, Kristen Sweet, Diane D Harrison, Elizabeth C Hsia, Désirée van der Heijde
OBJECTIVES: The efficacy and safety of ustekinumab were evaluated in 3 randomized, placebo-controlled studies in patients with axial spondyloarthritis (axSpA). The first 2 studies included patients with radiographic axSpA (Study 1 [anti-tumor necrosis factor (TNF)-naïve]; Study 2 [anti-TNF refractory]), and Study 3 patients had non-radiographic axSpA. METHODS: In all 3 studies, patients were randomly assigned (1:1:1) to receive subcutaneous ustekinumab 45mg or 90mg or placebo up to 24 weeks, after which placebo-treated patients were rerandomized to receive ustekinumab 45mg or 90mg...
September 18, 2018: Arthritis & Rheumatology
Nobuaki Chinzei, Muhammad Farooq Rai, Shingo Hashimoto, Eric J Schmidt, Ken Takebe, James M Cheverud, Linda J Sandell
OBJECTIVE: Recombinant inbred (RI) mouse strains generated from a LG/J and SM/J intercross offer a unique resource to study complex genetic traits such as osteoarthritis (OA). We determined the susceptibility of 14 strains to various phenotypes characteristic of post-traumatic OA (PTOA). We hypothesize that phenotypic variability is associated with genetic variability. METHODS: 10-week old male mice underwent destabilization of the medial meniscus (DMM) to induce PTOA...
September 18, 2018: Arthritis & Rheumatology
Claas H Hinze, Dirk Foell, Anne L Johnson, Steven J Spalding, Beth S Gottlieb, Paula W Morris, Yukiko Kimura, Karen Onel, Suzanne C Li, Alexei A Grom, Janalee Taylor, Hermine I Brunner, Jennifer L Huggins, James J Nocton, Kathleen A Haines, Barbara S Edelheit, Michael Shishov, Lawrence K Jung, Calvin B Williams, Melissa S Tesher, Denise M Costanzo, Lawrence S Zemel, Jason A Dare, Murray H Passo, Kaleo C Ede, Judyann C Olson, Elaine A Cassidy, Thomas A Griffin, Linda Wagner-Weiner, Jennifer E Weiss, Larry B Vogler, Kelly A Rouster-Stevens, Timothy Beukelman, Randy Q Cron, Daniel Kietz, Kenneth Schikler, Jay Mehta, Tracy V Ting, James W Verbsky, Anne B Eberhard, Bin Huang, Edward H Giannini, Daniel J Lovell
OBJECTIVE: To determine the relationship between serum S100A8/A9 and S100A12 and the maintenance of clinical inactive disease (CID) in patients with polyarticular forms of juvenile idiopathic arthritis (PF-JIA) while on anti-tumor necrosis factor therapy (anti-TNF) and disease flare following withdrawal of anti-TNF. METHODS: In this prospective, multicenter study, 137 patients with PF-JIA were enrolled while in CID on anti-TNF. Patients were observed for the initial 6 months...
September 18, 2018: Arthritis & Rheumatology
April Jorge, Zachary S Wallace, Yuqing Zhang, Na Lu, Karen H Costenbader, Hyon K Choi
BACKGROUND/OBJECTIVE: The premature mortality among patients with end-stage renal disease due to lupus nephritis (LN-ESRD) persisted in the U.S. between 1995 and 2006. We extended the analysis until 2014 for the latest trend and also examined key cause-specific mortality trends. METHODS: Using the national registry of ESRD patients, we identified all patients with incident LN-ESRD between January 1, 1995 and December 31, 2014, divided into four five-year cohorts by calendar year of ESRD onset (1995-1999, 2000-2004, 2005-2009, 2010-2014)...
September 18, 2018: Arthritis & Rheumatology
Meggan Mackay, Maria Dall'Era, Joanna Fishbein, Kenneth Kalunian, Martin Lesser, Jorge Sanchez Guerrero, Deborah M Levy, Earl Silverman, Michelle Petri, Cristina Arriens, Edmund J Lewis, Stephen M Korbet, Fabrizio Conti, Vladimir Tesar, Zdenka Hruskova, Eduardo F Borba, Eloisa Bonfa, Tak Mao Chan, Manish Rathi, K L Gupta, Vivekanand Jha, Sarfaraz Hasni, Melissa R West, Elian Silverman, Neil Solomons, Frederic A Houssiau, Juanita Romera Diaz, Juan Mejia-Vilet, Brad H Rovin
OBJECTIVE: Endpoints currently used in lupus nephritis (LN) clinical trials lack uniformity and questionably reflect long-term kidney survival. The objective of this investigation was to identify short-term endpoints that predict long-term kidney outcomes for use in clinical trials. METHODS: A database of 944 LN patients was assembled from 3 clinical trials and 12 longitudinal cohorts. Variables from the first 12 months of treatment after diagnosis of active LN (prediction period) were assessed as potential predictors of long-term outcomes in a 36 month follow-up period...
September 17, 2018: Arthritis & Rheumatology
Giuseppina Abignano, Gianna A Mennillo, Giovanni Lettieri, Angela Padula, Dennis McGonagle, Salvatore D'Angelo
A 40-year-old gentleman was diagnosed with anti-topoisomerase-I antibody positive diffuse cutaneous systemic sclerosis (SSc). Raynaud's phenomenon, diffuse skin sclerosis and severe interstitial lung disease (ILD) were the onset features causing digital ischemia, disability and dyspnea. He subsequently developed inflammatory polyarthritis (IA) with hands and wrists involvement. His brother had psoriasis. Physical examination showed fingertip pitting scars, subcutaneous calcinosis, skin sclerosis with hyper- and hypopigmentation, flexion and extension contractures and shortened fingers (Figure 1...
September 17, 2018: Arthritis & Rheumatology
P A Bakker, S Ramiro, Z Ez-Zaitouni, M van Lunteren, I J Berg, R Landewé, R Ramonda, M van Oosterhout, M Reijnierse, F A van Gaalen, D van der Heijde
OBJECTIVE: To investigate the value of repeating MRI of the sacroiliac joints (MRI-SI) in the diagnostic process of early chronic back pain patients (CBP) suspected of axial SpondyloArthritis (axSpA) and study determinants of MRI-SI-positivity. METHODS: Patients with CBP (duration: ≥3 months, ≤2 year, onset <45 years) with ≥1 SpA-feature included in the SPondyloArthritis Caught Early cohort underwent baseline, three months and one year visits with evaluation of all SpA-features and repeated MRI-SI...
September 11, 2018: Arthritis & Rheumatology
Damien Sène, Sophie Ismael, Marine Forien, Frédéric Charlotte, Rachid Kaci, Patrice Cacoub, Diallo Abdourahmane, Philippe Dieudé, Frédéric Lioté
Thanks for giving us the opportunity to respond to the letter by Haacke et al (1). They discussed our article in which we have identified ectopic germinal centers (GC) structures in labial minor salivary glands as a significant predictor of non-Hodgkin's lymphoma (NHL) in patients with primary Sjögren's syndrome (pSS) (2). As discussed in our article, we agree that this finding is not consensual, with contradictory reports and we have analyzed the factors that might explained these discrepancies (2). This article is protected by copyright...
September 5, 2018: Arthritis & Rheumatology
Erlin A Haacke, Bert van der Vegt, Arjan Vissink, Fred K L Spijkervet, Hendrika Bootsma, Frans G M Kroese
With great interest we have read the article of Sène et al. (1) in which ectopic germinal centres (GCs) in labial gland biopsies of primary Sjögren syndrome (pSS) patients were found predictive for Non-Hodgkin's lymphoma (NHL) development later in the disease. In the univariate analysis the presence of GCs in these biopsies was not significantly different between pSS patients that developed NHL or pSS patients that did not. This article is protected by copyright. All rights reserved.
September 3, 2018: Arthritis & Rheumatology
Chisako Fujiwara, Akihito Uehara, Akiko Sekiguchi, Akihiko Uchiyama, Sahori Yamazaki, Sachiko Ogino, Yoko Yokoyama, Ryoko Torii, Mari Hosoi, Chiaki Suto, Katsuhiko Tsunekawa, Masami Murakami, Osamu Ishikawa, Sei-Ichiro Motegi
OBJECTIVE: Several studies have demonstrated that secreted glycoprotein and integrin ligand MFG-E8 negatively regulate fibrosis in the liver, lungs and respiratory tract. However, the mechanisms and roles of MFG-E8 in skin fibrosis in systemic sclerosis (SSc) have not been characterized. This study aimed to elucidate the role of MFG-E8 in skin fibrosis in SSc. METHODS: The expression of MFG-E8 in the skin and serum in SSc patients was assessed. The effect of rMFG-E8 on latent-TGF-β-induced gene/protein expression in SSc fibroblasts was examined...
September 3, 2018: Arthritis & Rheumatology
Milica Blagojevic-Bucknall, Christian Mallen, Sara Muller, Richard Hayward, Sophie West, Hyon Choi, Edward Roddy
OBJECTIVE: Obstructive sleep apnea (OSA) is associated with a range of serious comorbidities. This study investigates whether people with OSA are more likely to develop gout than those without OSA in both short and long term. METHODS: A matched retrospective cohort study was undertaken in the UK Clinical Practice Research Datalink. Individuals aged ≥18 years with an incident diagnosis of OSA between 1990 and 2010 were identified and matched on age, gender and practice to up to four individuals without OSA; follow-up was until end of 2015...
August 30, 2018: Arthritis & Rheumatology
Johanna Steen, Björn Forsström, Peter Sahlström, Victoria Odowd, Lena Israelsson, Akilan Krishnamurthy, Sara Badreh, Linda Mathsson Alm, Joanne Compson, Daniel Ramsköld, Welcome Ndlovu, Stephen Rapecki, Monika Hansson, Philip J Titcombe, Holger Bang, Daniel L Mueller, Anca I Catrina, Caroline Grönwall, Karl Skriner, Peter Nilsson, Daniel Lightwood, Lars Klareskog, Vivianne Malmström
OBJECTIVES: Antibodies against post-translationally modified (PTM) proteins are a hallmark of rheumatoid arthritis (RA), but the emergence and pathogenicity of these autoantibodies are still incompletely understood. We aimed to analyze the antigen specificities and mutation patterns of monoclonal antibodies derived from RA synovial plasma cells and address the question of antigen cross reactivity. METHODS: IgG secreting cells were isolated from RA synovial fluid, and the variable regions of the immunoglobulins were sequenced (n=182) and expressed in full-length antibodies (n=93) and also as germline reverted versions...
August 27, 2018: Arthritis & Rheumatology
N Groot, D Shaikhani, Y K O Teng, K de Leeuw, M Bijl, R J E M Dolhain, E Zirkzee, R Fritsch-Stork, I E M Bultink, S Kamphuis
OBJECTIVE: Childhood-onset SLE (cSLE) is a severe lifelong multisystem autoimmune disease. Long-term outcome data are limited. Here, we report clinical characteristics and health-related quality of life (HRQOL) of adults with cSLE. METHODS: Patients underwent a single study visit comprising a structured history and physical examination. Disease activity (SLEDAI-2K), damage (SLICC-Damage Index (SDI)) and HRQOL (SF-36) were determined. Medical records were retrieved...
August 27, 2018: Arthritis & Rheumatology
Changrong Ge, Bingze Xu, Bibo Liang, Erik Lönnblom, Susanna L Lundström, Roman A Zubarev, Burcu Ayoglu, Peter Nilsson, Thomas Skogh, Alf Kastbom, Vivianne Malmström, Lars Klareskog, René E M Toes, Theo Rispens, Doreen Dobritzsch, Rikard Holmdahl
OBJECTIVES: Anti-citrullinated protein antibodies (ACPAs) develop many years before the clinical onset of rheumatoid arthritis. Here we addressed the molecular basis of the specificity and cross-reactivity of ACPAs from patients with rheumatoid arthritis (RA). METHODS: Antibodies isolated from RA patients were expressed as monoclonal chimeric antibodies with mouse Fc and characterized for glycosylation using mass-spectrometry and cross-reactivity using Biacore and Luminex immunoassay...
August 27, 2018: Arthritis & Rheumatology
Isaac T Cheng, Qing Shang, Edmund K Li, Priscilla C Wong, Emily W Kun, Mei Yan Law, Ronald M Yip, Isaac C Yim, Billy T Lai, Shirley K Ying, Kitty Y Kwok, Martin Li, Tena K Li, Tracy Y Zhu, Jack J Lee, Mimi M Chang, Cheuk-Chun Szeto, Bryan P Yan, Alex P Lee, Lai-Shan Tam
OBJECTIVES: We aimed to investigate the effects of achieving minimal disease activity (MDA) on the progression of subclinical atherosclerosis and arterial stiffness in patients with psoriatic arthritis (PsA). METHODS: 101 consecutive PsA patients were recruited for this prospective cohort study. All patients received protocolized treatment targeting MDA for a period of 2 years. High-resolution carotid ultrasound and arterial stiffness markers were assessed annually...
August 25, 2018: Arthritis & Rheumatology
Wensheng Wang, Xi Lin, Hao Xu, Wen Sun, Echoe M Bouta, Michael J Zuscik, Di Chen, Edward M Schwarz, Lianping Xing
OBJECTIVE: To investigate roles of the synovial lymphatic system in tissue damage, macrophage subsets, and the therapeutic potential of proteasome inhibitor Bortezomib (Btz) in a mouse model of experimental post-traumatic OA (PTOA). METHODS: C57BL/6J wild type mice received a meniscal-ligamentous injury to induce PTOA. Lymphangiogenesis was blocked by a vascular endothelial growth factor receptor 3 (VEGFR3) neutralizing antibody. Synovial lymphatic drainage was examined by near-infrared imaging...
August 25, 2018: Arthritis & Rheumatology
Lindsey A MacFarlane, Heidi Yang, Jamie E Collins, Mohamed Jarraya, Ali Guermazi, Lisa A Mandl, Scott D Martin, John Wright, Elena Losina, Jeffrey N Katz
OBJECTIVE: Synovitis is a feature of knee osteoarthritis (OA) and meniscal tear and has been associated with articular cartilage damage. Our study examined the associations between baseline and changes in effusion-synovitis and changes in cartilage damage in a cohort with OA and meniscal tear. METHODS: We analyzed data from the Meniscal Tear in Osteoarthritis Research (MeTeOR) trial of surgery vs. physical therapy for treatment of meniscal tear. We performed semiquantitative grading of effusion-synovitis and cartilage damage on magnetic resonance imaging (MRI), and dichotomized effusion-synovitis as none/small ('minimal') and medium/large ('extensive')...
August 22, 2018: Arthritis & Rheumatology
Michelle Petri, Laurence S Magder
We agree that the GLIADEL group took a different approach than ours. First, we used Lupus Low Disease Activity State (LLDAS) as defined by Franklyn et al. (1) Basically, if a patient was in remission, they would also be in LLDAS. This article is protected by copyright. All rights reserved.
August 18, 2018: Arthritis & Rheumatology
Manuel F Ugarte-Gil, Daniel Wojdyla, Guillermo J Pons-Estel, Bernardo A Pons-Estel, Graciela S Alarcón
We read with great interest the report from Petri et al (1) on the impact of remission and lupus low disease activity state (LLDAS) in damage accrual in patients with lupus and would like to congratulate the authors on their work. In this single center cohort from Hopkins, followed for approximately 30 years (1987 to 2016), with patients having a mean disease duration at cohort entry of two years, these authors found that being on remission (with or without treatment) for any time prevented damage accrual, and being on LLDAS for at least 25% of the time also prevented damage accrual...
August 18, 2018: Arthritis & Rheumatology
Devyani Misra, Roger A Fielding, David T Felson, Jingbo Niu, Carrie Brown, Michael Nevitt, Cora E Lewis, James Torner, Tuhina Neogi
OBJECTIVE: Obesity, defined by anthropometric measures, is a well-known risk factor for knee osteoarthritis (OA) but there is a relative paucity of data regarding the association of body composition (fat and muscle mass) on knee OA risk. We examined the longitudinal association of body composition categories based on fat and muscle mass with incident knee OA risk. METHODS: We included participants from The Multicenter Osteoarthritis (MOST) Study, a longitudinal cohort of individuals with or at risk for knee OA...
August 14, 2018: Arthritis & Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"